MAZEPINE 200 MG — DIN 00504742
CARBAMAZEPINE : 200 MG · BIOMED PHARMA · TABLET · wholesale supply in Canada
Health Canada status: DORMANT
What is MAZEPINE?
MAZEPINE 200 MG contains CARBAMAZEPINE : 200 MG. It is listed in the Health Canada Drug Product Database under DIN 00504742, held by BIOMED PHARMA, supplied as TABLET for ORAL administration. Health Canada currently lists it as dormant, status dated 04-Aug-2017. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A). This DIN is not currently being marketed in Canada, so it is sourced to order where a compliant route exists rather than held in stock.
What is MAZEPINE used for?
Anticonvulsant for partial and generalized tonic-clonic seizures. Symptomatic relief of pain in true trigeminal neuralgia (tic douloureux) and glossopharyngeal neuralgia.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
How much does Carbamazepine cost around the world?
Carbamazepine is listed on 11 of the national price registers Nexara ingests. Each country publishes on a different basis, so figures are not comparable with one another — or with a Canadian wholesale price.
What a market publishes matters more than the number it publishes. Australia publishes a ex-manufacturer; Austria publishes a KVP (Kassenverkaufspreis); Bahrain publishes a retail (max). Comparing an ex-factory ceiling against a pharmacy public price tells you nothing about either, and comparing either against a Canadian landed cost tells you less.
| Market | Price basis published there | Brands | Packs listed |
|---|---|---|---|
| United States | acquisition | 3 | 31 |
| Australia | ex-manufacturer | 6 | 21 |
| South Africa | single exit price | 13 | 19 |
| Saudi Arabia | public | 13 | 15 |
| Austria | KVP (Kassenverkaufspreis) | 9 | 13 |
| Czechia | max producer price (ex-factory) | 5 | 11 |
| United Arab Emirates | public | 5 | 5 |
| Bahrain | retail (max) | 3 | 5 |
| Morocco | PPV (public price) | 3 | 5 |
| Greece | producer price (ex-factory) | 4 | 4 |
| Luxembourg | reimbursement | 4 | 4 |
133 pack listings across 68 brand entries and 10 price bases, refreshed 08 Sep 2026. Ranges span every Carbamazepine pack in that market, so a high figure is usually a larger pack rather than the same product.
Canada publishes no comparable public list price. For a delivered Canadian price on a licensed account, verify your licence — it takes about a minute.
Is there a generic Carbamazepine in Canada, and who makes it?
Every market authorization holder with a Canadian DIN for this molecule, and how many of their listings Health Canada currently shows as marketed.
14 holders have a Canadian DIN containing Carbamazepine, across 46 DINs, of which 11 are currently marketed. Marketed count is the number that matters: an approval that is not marketed cannot be bought.
| Market authorization holder | DINs | Marketed | Brand names | Position |
|---|---|---|---|---|
| NOVARTIS PHARMACEUTICALS CANADA INC | 6 | 4 | TEGRETOL, TEGRETOL CHEWTABS 100 MG, TEGRETOL CHEWTABS 200 MG, TEGRETOL CR, TEGRETOL SUSPENSION | Sourceable in Canada |
| TARO PHARMACEUTICALS INC | 7 | 3 | TARO-CARBAMAZEPINE, TARO-CARBAMAZEPINE CHEWABLE TABLETS, TARO-CARBAMAZEPINE CR, TARO-CARBAMAZEPINE TAB 200MG | Sourceable in Canada |
| SANDOZ CANADA INCORPORATED | 4 | 2 | SANDOZ-CARBAMAZEPINE CHEWTABS, SANDOZ-CARBAMAZEPINE CR | Sourceable in Canada |
| MINT PHARMACEUTICALS INC | 1 | 1 | MINT-CARBAMAZEPINE | Sourceable in Canada |
| TEVA CANADA LIMITED | 1 | 1 | TEVA-CARBAMAZEPINE | Sourceable in Canada |
| PHARMASCIENCE INC | 8 | 0 | PMS-CARBAMAZEPINE, PMS-CARBAMAZEPINE CR, PMS-CARBAMAZEPINE-CR | No marketed DIN |
| PRO DOC LIMITEE | 5 | 0 | CARBAMAZEPINE 200 TAB 200MG, CARBAMAZEPINE CR, CARBAMAZEPINE-CR -(200MG), CARBAMAZEPINE-CR -(400MG) | No marketed DIN |
| APOTEX INC | 3 | 0 | APO-CARBAMAZEPINE, APO-CARBAMAZEPINE CR | No marketed DIN |
| DOMINION PHARMACAL | 3 | 0 | DOM-CARBAMAZEPINE, DOM-CARBAMAZEPINE CR | No marketed DIN |
| BIOMED PHARMA | 2 | 0 | BIO-CARBAMAZEPINE, MAZEPINE | No marketed DIN |
| MYLAN PHARMACEUTICALS ULC | 2 | 0 | MYLAN-CARBAMAZEPINE CR | No marketed DIN |
| PHARMEL INC | 2 | 0 | PHL-CARBAMAZEPINE CR | No marketed DIN |
Health Canada’s Drug Product Database does not flag which listing is the originator and which are subsequent-entry products, so Nexara does not label them here. Interchangeability is determined provincially, not federally — confirm for your province before a formulary switch. Nexara can confirm which of these is actually obtainable, and on what lead time, per order.
How is it supplied and stored?
Pack configuration, storage class and the handling constraints that drive cold-chain planning. One DIN can cover more than one pack size, and the pack — not the DIN — is what gets priced, shipped and invoiced.
| Strength on the label | 200 MG |
|---|---|
| Dosage form | TABLET |
| Route | ORAL |
| Pack configuration (monograph) | Not explicitly detailed in provided text (mentions 'smallest quantity of tablets' for safety). |
| Storage | Not explicitly detailed in provided text (standard USP storage usually 15-30°C). |
Before an order line is unambiguous Nexara needs the strength, the pack size and the presentation.
Substance and classification
| Active substance | Carbamazepine |
|---|---|
| ATC code | N03AF01 |
| Biosimilar biologic | No |
Health Canada record and identifiers
The regulatory facts straight from the Drug Product Database, plus every identifier form Nexara accepts on a purchase order. A DIN written without its leading zeros is the commonest reason an order line fails to match.
| DIN (8-digit, as used in ordering) | 00504742 |
|---|---|
| DIN (unpadded, as printed on some documents) | 504742 |
| Brand name | MAZEPINE |
| Generic / active ingredient | CARBAMAZEPINE : 200 MG |
| Market authorization holder | BIOMED PHARMA |
| Health Canada schedule | Prescription |
| ATC code | N03AF01 |
| ATC anatomical main group | N — Nervous system |
| ATC therapeutic subgroup | N03AF |
| Current status | DORMANT |
| Status date | 04-Aug-2017 |
| Original market date | 1980-12-31 00:00:00 |
| Status source | Live Health Canada DPD sync |
Verify on the primary sources
How is it administered?
Epilepsy: Initially 100-200 mg 1-2 times daily, increasing to 800-1200 mg/day. Trigeminal Neuralgia: Initially 100 mg twice daily, increasing until pain relief (usually 200 mg 3-4 times daily).
Included because it drives pack selection and wastage. Consult the monograph.
Contraindications
Hepatic disease, history of bone-marrow depression, hepatic porphyria, serious blood disorder, AV heart block, hypersensitivity to carbamazepine or tricyclic compounds, use with MAOIs or voriconazole.
Warnings and precautions
Serious hematologic (aplastic anemia, agranulocytosis) and dermatologic (SJS/TEN) reactions. HLA-A*3101 and HLA-B*1502 genotyping recommended for at-risk populations. Risk of suicidal ideation.
What can be used instead?
Alternatives on every axis a buyer actually considers — the same molecule in another presentation, the same class, an adjacent class, or a fixed-dose combination. Every row is led by the marketed DIN count, because that is what can be bought this week.
1 · Same molecule, other Canadian presentations
11 of 46 Canadian DINs for this molecule are currently marketed. Marketed products are listed first.
| Product | Strength | Form | Holder | Health Canada status | DIN |
|---|---|---|---|---|---|
| MINT-CARBAMAZEPINE | 200 MG | TABLET | MINT PHARMACEUTICALS INC | MARKETED | 02541238 |
| SANDOZ-CARBAMAZEPINE CR | 400 MG | TABLET (EXTENDED-RELEASE) | SANDOZ CANADA INCORPORATED | MARKETED | 02261847 |
| SANDOZ-CARBAMAZEPINE CR | 200 MG | TABLET (EXTENDED-RELEASE) | SANDOZ CANADA INCORPORATED | MARKETED | 02261839 |
| TARO-CARBAMAZEPINE | 100 MG / 5 ML | SUSPENSION | TARO PHARMACEUTICALS INC | MARKETED | 02367394 |
| TARO-CARBAMAZEPINE CHEWABLE TABLETS | 100 MG | TABLET (CHEWABLE) | TARO PHARMACEUTICALS INC | MARKETED | 02244403 |
| TARO-CARBAMAZEPINE CHEWABLE TABLETS | 200 MG | TABLET (CHEWABLE) | TARO PHARMACEUTICALS INC | MARKETED | 02244404 |
| TEGRETOL | 200 MG | TABLET | NOVARTIS PHARMACEUTICALS CANADA INC | MARKETED | 00010405 |
| TEGRETOL CR | 400 MG | TABLET (EXTENDED-RELEASE) | NOVARTIS PHARMACEUTICALS CANADA INC | MARKETED | 00755583 |
| TEGRETOL CR | 200 MG | TABLET (EXTENDED-RELEASE) | NOVARTIS PHARMACEUTICALS CANADA INC | MARKETED | 00773611 |
| TEGRETOL SUSPENSION | 100 MG / 5 ML | SUSPENSION | NOVARTIS PHARMACEUTICALS CANADA INC | MARKETED | 02194333 |
2 · Same class — other molecules in ATC N03AF
| Molecule | Canadian brands | DINs | Marketed | Sourceable |
|---|---|---|---|---|
| Carbamazepine | APO-CARBAMAZEPINE · APO-CARBAMAZEPINE CR · BIO-CARBAMAZEPINE · CARBAMAZEPINE 200 TAB 200MG · +26 more | 46 | 11 | Yes |
| Oxcarbazepine | APO-OXCARBAZEPINE · JAMP OXCARBAZEPINE · JAMP-OXCARBAZEPINE · NOVO-OXCARBAZEPINE · +6 more | 22 | 9 | Yes |
| Eslicarbazepine | APO-ESLICARBAZEPINE · APTIOM · AURO-ESLICARBAZEPINE | 12 | 8 | Yes |
| Rufinamide | AURO-RUFINAMIDE · BANZEL | 6 | 5 | Yes |
A molecule with zero marketed DINs cannot be sourced domestically, however many approvals it holds — if one of these sits on a formulary or in an older protocol, that is the line to check.
3 · Adjacent classes in ATC N03A
| ATC subgroup | Molecules | DINs | Marketed |
|---|---|---|---|
| N03AX | Brivaracetam · Cannabidiol · Cenobamate · Lacosamide · Lamotrigine · +4 more | 391 | 197 |
| N03AG | Valproic Acid · Vigabatrin | 75 | 19 |
| N03AA | Phenobarbital · Primidone | 39 | 13 |
| N03AB | Fosphenytoin · Phenytoin · Phenytoin, Combinations | 17 | 8 |
| N03AE | Clonazepam | 55 | 8 |
| N03AD | Ethosuximide · Mesuximide | 5 | 4 |
Not clinical advice. These tables describe what can be supplied in Canada, not what should be prescribed. Substitution within or across classes is a prescriber and pharmacist decision, and interchangeability is determined provincially.
What else is MAZEPINE called?
The same molecule, Carbamazepine, is registered under other names elsewhere. Buyers and prescribers searching from outside Canada — or working from a foreign prescription or tender document — often know it by one of these:
| Name | Script | Registered in |
|---|---|---|
| AVLOIRE | Latin | Australia |
| Tegretol | Latin | Bahrain, Morocco, South Africa |
| TEGRETOL CR | Latin | Bahrain, Czechia |
| TIMONIL RETARD | Latin | Czechia |
| NEUROTOP RETARD | Latin | Czechia |
| Tegretol Liquid | Latin | Australia |
| Carbalept | Latin | Saudi Arabia |
| Carbatol | Latin | Bahrain, Saudi Arabia |
| CRIZEPINE | Latin | Morocco |
| TEGRETOL LP | Latin | Morocco |
| BISTON | Latin | Czechia |
| Degranol | Latin | South Africa |
| NEUROTOP | Latin | Czechia |
| Tegretol orale Susp. | Latin | Austria |
| Tegretol S | Latin | South Africa |
Names are taken from national medicine registers and published price lists. A product registered abroad is not authorized for sale in Canada unless it holds its own DIN; import is possible only through the routes Health Canada permits.
How can I get it?
This DIN is dormant — it holds a Health Canada authorization but is not currently being marketed in Canada, so it cannot simply be ordered from Canadian stock. Where a patient need exists, supply may be possible through exceptional importation or the Special Access Programme, subject to Health Canada's requirements and the prescriber's application. Nexara can advise on the route and on marketed alternatives.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address. Patients and unlicensed buyers are routed to a partner pharmacy.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Why is there no price on this page?
Nexara quotes a delivered Canadian price per order, against a verified licence. Foreign list prices are published on incompatible bases and are not a guide to what any buyer can obtain here, so this page shows which markets list the molecule and on what basis, and nothing more.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.